Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

Author: Avi Kapoor | January 08, 2024 08:13am

Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

STAAR Surgical

  • The Trade: STAAR Surgical Company (NASDAQ:STAA) 10% owner Neal Bradsher acquired a total of 226,553 shares an average price of $28.61. To acquire these shares, it cost around $6.48 million.
  • What’s Happening: Staar Surgical, during November, posted better-than-expected quarterly earnings.
  • What STAAR Surgical Does: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye.

KalVista Pharmaceuticals

  • The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) 10% owner Nimish Shah acquired a total of 59,369 shares at an average price of $12.14. To acquire these shares, it cost around $720,543.
  • What’s Happening: KalVista Pharma, last month, announced publication of first oral factor XIIa data in Frontiers in Pharmacology.
  • What KalVista Pharmaceuticals Does: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.

Don’t forget to check out our premarket coverage here

NB Bancorp

  • The Trade: NB Bancorp, Inc. (NASDAQ:NBBK) Director Muhammad Raza bought a total of 3,706 shares at an average price of $13.50. To acquire these shares, it cost around $50,031.
  • What’s Happening: The company’s stock fell around 1% over the past five days.
  • What NB Bancorp Does: NB Bancorp Inc operates as the holding company of Needham Bank.

 

Check This Out: Commercial Metals, Boot Barn And 3 Stocks To Watch Heading Into Monday

Posted In: KALV NBBK STAA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist